Women with primary breast cancer are commonly treated with chemotherapy and with endocrine therapy in addition to surgery to reduce the risk of disease recurrence. Chemotherapy is usually reserved for patients at higher risk. It is clear however that many patients don’t benefit from chemotherapy despite its side effects and costs. The OPTIMA trial will evaluate multi-parameter pathology tests that could offer improved identification of patients who might benefit from chemotherapy. Specifically it will examine whether these tests provide equivalent outcomes for patients, but with lower use of chemotherapy and lower total costs of care including the costs of the tests.
ICPV Has been involved with this trial from the start most recently with the organisation of Focus Groups on behalf of the team at Warwick.
Adrienne Morgan is part of the project team and is named as a co-author on the recent launch paper - see below
For more information go to http://www.hta.ac.uk/project/2791.asp
2017 Summer School
The 2017 ICPV Summer School was held over two days in June at Stirling University. The theme of the event was Cancer Survivorship and Living Well Cancer. Click below for details of the course. More details.
A snapsot video of the the 2016 course is now available on YouTube VOICE2016
At the BACR/ECMC conference in July Maggie Wilcox and Mairead Mackenzie were persuaded to speak to the camera. Maggie gave a background to ICPV and our aims and objectives. While Mairead focused on her specific interests and activities. To view follow the links below.
July 2016 Conferences
ICPV members were busy this week with two conferences. The BACR/ECMC Joint Meeting on Therapeutic Interventions for Cancer Prevention was held in Bristol July18-19. The UK Breast Cancer Research Symposium was held in London from July 22-23. Click here for more information.
UK Therapeutic Cancer Prevention Network (UKTCPN)
An update from this new group was presented to the ECMC Annual Network Meeting in May 2016. Click here to download and read.
Call for immediate change to European Paediatric Medicine Regulation to save more lives of children and teens with cancer.
A few basic changes to European Law could speed up access to newer, kinder and potentially better drugs for more children and teenagers with cancer. Click to Sign the petition
Two years on from the start pioneering TRACERx lung cancer study. Click here For the latest news and patient views on this study.